Ayming Webinar – Biotech: what Federal Budget 2026 means for SR&ED, IP costs and funding through long development cycles
November 25 @ 12:00 pm - 1:00 pm
What is it
Federal Budget 2026 adds regulatory testing and IP protection costs to SR&ED, backed by $930 million over five years. BIOTECanada members are invited to hear Ayming Canada’s specialists explain what it means for biotech companies.
This is Ayming’s own analysis, not a recap of the government’s budget: what matters, what is still unclear, and a 90-day action plan. Ayming’s funding and tax specialists will cover the measures that matter for companies with long development timelines and share a 90-day plan.
What members will take away
- SR&ED changes: which regulatory testing, certification and IP protection costs may qualify, and how to start documenting them. For calendar-year companies, the change applies from January 1, 2027.
- Equipment and facilities: how the Productivity Mega Deduction could affect lab and manufacturing investments, and the open question on intangible assets.
- A 90-day plan: the first moves to make before year-end, in the order Ayming would make them.
First access for registrants: everyone who registers receives first access to Ayming’s Federal Budget 2026 report.
About Ayming Canada
Ayming Canada helps businesses secure SR&ED tax credits, government funding and innovation incentives. With 40 years of expertise in government funding and tax incentives, Ayming helps you engineer your projects and secure the financial support you need to grow and innovate. Pioneers in Canada, they were the first consulting firm to establish a national grant practice dedicated to maximizing public funding opportunities. They secure $1.5 billion annually in funding for their clients, achieving a 98.5% success rate on claims submitted. With flexible engagement models and end-to-end support, from identifying opportunities to managing claims, they act as an extension of your team, maximizing results.
